NFE2L2 and cancer: Herein, we sought to examine the landscape of NFE2L2 mutations and Nrf2-activating mutations, in 49,533 patients in a pan-cancer cohort (OrigiMed cohort) and the other two pan-cancer cohorts (the Memorial Sloan Kettering-Metastatic Events and Tropisms [MSK MetTropism] and the cancer genome atlas [TCGA] cohorts) and their association with clinical outcomes [28].